Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

1292PALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA

(2017) S. Gettinger et al.   ANNALS OF ONCOLOGY

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib

(2014) Qinhua Huang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

(2014) Shirish M Gadgeel et al.   LANCET ONCOLOGY

Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy

(2014) Kilian V. M. Huber et al.   NATURE

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

ROS1-Rearranged Lung Cancer

(2013) Akihiko Yoshida et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Identification ofROS1rearrangement in gastric adenocarcinoma

(2013) Jeeyun Lee et al.   CANCER

Molecular Pathways: ROS1 Fusion Proteins in Cancer

(2013) K. D. Davies et al.   CLINICAL CANCER RESEARCH

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

(2013) Thomas H. Marsilje et al.   JOURNAL OF MEDICINAL CHEMISTRY

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

(2013) Mark M. Awad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions

(2013) J. F. Gainor et al.   ONCOLOGIST

Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer

(2013) Kurtis D. Davies et al.   PLoS One

Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer

(2012) K. D. Davies et al.   CLINICAL CANCER RESEARCH

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer

(2012) Hiroyuki Yasuda et al.   Journal of Thoracic Oncology

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma

(2011) Ting-Lei Gu et al.   PLoS One

Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours

(2011) Ashley H. Birch et al.   PLoS One

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

(2008) U. McDermott et al.   CANCER RESEARCH